US Biotechnology: Reminder: CEO Call Series: Conversation with AGIO management TOMORROW

Research evidence excerpt

US Biotechnology: Reminder: CEO Call Series: Conversation with AGIO management TOMORROW

Accessible version

US Biotechnology

Reminder: CEO Call Series: Conversation

with AGIO management TOMORROW

Invitation

Topic 20 July 2026

We are hosting the management team from Agios Pharmaceuticals (AGIO), including Equity

Brian Goff, CEO, and Dr. Krishnan Viswanadhan, CSO/COO, to run through key stock United States

drivers and recent updates ahead of 2Q earnings. Agios has had a wealth of recent Biotechnology

updates (see eight reports we’ve written on Agios in the past few months linked in this

Related Researchinvitation). Our conversation with Agios management will focus on: 1) expectations

US Biotechnology: 2Q26 Earnings Preview:

heading into 2Q earnings in thalassemia and pyruvate-kinase deficiency (PKD), 2) MRNA, TGTX, CRSP, AGIO, NVAX, & HCM 07

regulatory outlook for sickle cell disease (SCD) and EU labeling/expansion, 3) recent data July 2026

updates at the European Hematology Association (EHA) congress and setup into 2H26 Agios Pharmaceuticals: EHA update

data catalysts (tebapivat in SCD, etc.), and 4) early stage programs including newly strengthens SCD path ahead of imminent

sNDA acceptance

acquired CYK inhibitor Cevidoplenib. The conversation will be contextualized within the Agios Pharmaceuticals: Takeaways from our

broader hematology landscape, key debates about commercial opportunity/viability, and thalassemia expert call on AQVESME launch

where the next legs of growth could come from within the pipeline. outlook

Agios Pharmaceuticals: Thalassemia

Host Speaker(s) Date and Time prescriber survey bullish on AQVESME launch, limited REMS impact

Alec Stranahan, US SMid-cap Tuesday, July 21, 2026 11:00 AM Eastern Time Agios Pharmaceuticals: Tebapivat LR-MDS